Complement Inhibitors - Empaveli
Customize your policy alerts
Sign up for Cigna Policy IP0194 alerts
Get alerted when Policy IP0194 changes without checking for updates manually.
Monitor payer policy activity
Defines Cigna's prior authorization, coverage criteria, and clinical context for Empaveli (pegcetacoplan) for C3 glomerulopathy, primary immune-complex membranoproliferative glomerulonephritis, and paroxysmal nocturnal hemoglobinuria; applies to health benefit plans administered by Cigna Companies.
Conditions Not Covered: Voydeya was added to the list of medications that should not be used concomitantly with Empaveli.
For patients currently receiving Empaveli, examples of benefit were updated to include improvement in FACIT‑Fatigue score.
Biosimilars to Soliris (eculizumab) were added to criteria addressing concomitant use and Conditions Not Covered.
Complement 3 Glomerulopathy (C3G) was added as an FDA-approved indication to the policy with documentation required.
PiaSky (crovalimab-akkz) was added to the list of medications that should not be used concomitantly with Empaveli.
Documentation requirements for confirmation of diagnosis were added.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.